Clinical Research Papers:

Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers

Seyoung Seo, Seong Joon Park, Min-Hee Ryu, Sook Ryun Park, Baek-Yeol Ryoo, Young Soo Park, Young-Soon Na, Chae-Won Lee, Ju-Kyung Lee and Yoon-Koo Kang _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:33844-33854. https://doi.org/10.18632/oncotarget.12953

Metrics: PDF 1313 views  |   HTML 2127 views  |   ?  


Seyoung Seo1,*, Seong Joon Park1,*, Min-Hee Ryu1,*, Sook Ryun Park1, Baek-Yeol Ryoo1, Young Soo Park2, Young-Soon Na3, Chae-Won Lee3, Ju-Kyung Lee3 and Yoon-Koo Kang1

1 Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

2 Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

3 Asan Institute for Life Science, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

* Seyoung Seo, Seong Joon Park, Min-Hee Ryu have contributed equally to this study as first authors

Correspondence to:

Yoon-Koo Kang, email:

Keywords: FGFR2; amplification; advanced gastric cancer; prognosis; quantitative real-time polymerase chain reaction

Received: July 20, 2016 Accepted: October 22, 2016 Published: October 27, 2016


Although Fibroblast growth factor receptor (FGFR) 2 gene amplification and its prognostic significance have been reported in resectable gastric cancers, information on these features remains limited in the metastatic setting. The presence of FGFR2 amplification was assessed in formalin-fixed, paraffin-embedded tissues using a quantitative PCR-based gene copy number assay with advanced gastric cancer cohorts. A total of 327 patients with tumor portion of ≥70% were analyzed for clinical features. Among these patients, 260 who received first-line fluoropyrimidine and platinum chemotherapy were analyzed for survival.

Sixteen of 327 patients (4.9%) exhibited FGFR2 amplification. The amplification group showed associations with age <65 years, Borrmann type 4 disease, poor performance status, poorly differentiated histology, extra-abdominal lymph node metastases, and bone metastases. The median overall survival (OS) and progression-free survival (PFS) were found to be 12.7 and 5.8 months, respectively. In univariate analysis, PFS did not differ between amplification and no amplification groups (hazard ratio [HR]=1.34, 95% confidence interval [CI]: 0.78-2.31, p=0.290), although the OS was significantly shorter in the amplification group (HR=1.92, 95% CI: 1.13-3.26, p=0.015). However, multivariate analysis indicated that FGFR2 amplification was not an independent prognostic factor for OS (HR=1.42, 95% CI: 0.77-2.61, p=0.261).

Although FGFR2 amplification is associated with poorer OS, it does not appear to be an independent prognostic predictor in patients with advanced gastric cancer treated with palliative fluoropyrimidine and platinum chemotherapy.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12953